VistA-internationalization/TranslationSpreadsheets/WV-DIALOG-0235.txt

308 lines
12 KiB
Plaintext

English French Notes Complete/Exclude
FIRST COURSE OF TREATMENT - RADIATION
38. REGIONAL DOSE (cGy)...........:
39. BOOST DOSE (cGy)..............:
40. INTRA-OPERATIVE RADIATION
41. CONCURRENT CHEMOTHERAPY.......:
FIRST COURSE OF TREATMENT - CHEMOTHERAPY
42. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
43. INTRAPERITONEAL CHEMOTHERAPY..:
44. CHEMOTHERAPEUTIC TOXICITY.....:
45. CHEMOTHERAPY/SURGERY SEQUENCE.:
FIRST COURSE OF TREATMENT - IMMUNOTHERAPY
46. ADMINISTRATION OF INTERFERON..:
TREATMENT COMPLICATIONS
CASE REGISTRATION
48. INITIALS OF CASE ABSTRACTOR...:
49. DATE CASE WAS ABSTRACTED......:
The Accession Year is not 2000.
2000 Patient Care Evaluation Study of Hepatocellular Cancers
1. FACILITY ID NUMBER (FIN)
5. PLACE OF BIRTH
6. DATE OF BIRTH
8. SPANISH ORIGIN
10. PRIMARY PAYER AT DIAGNOSIS
1. FACILITY ID NUMBER (FIN)
5. PLACE OF BIRTH
6. DATE OF BIRTH
8. SPANISH ORIGIN
1. FACILITY ID NUMBER (FIN)......:
2. ACCESSION NUMBER..............:
3. SEQUENCE NUMBER...............:
9 4. POSTAL CODE AT DIAGNOSIS......
7 5. PLACE OF BIRTH................
6. DATE OF BIRTH.................:
9 8. SPANISH ORIGIN................
18 10. PRIMARY PAYER AT DIAGNOSIS....
11. CLASS OF CASE
13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS
14. ALCOHOL CONSUMPTION
15. TUMOR MARKERS
16. TESTS RELATED TO LIVER FUNCTION
17. RADIOLOGICAL EVALUATION
18. DEFINITIVE DIAGNOSIS
19. DATE OF INITIAL DIAGNOSIS
22. DIAGNOSTIC CONFIRMATION
TUMOR IDENTIFICATION
11. CLASS OF CASE.................:
1000 ORAL CONTRACEPTIVES..........
1001 ESTROGEN REPLACEMENT.........
13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS:
1012 14. ALCOHOL CONSUMPTION...........
15. TUMOR MARKERS:
16. TESTS RELATED TO LIVER FUNCTION:
17. RADIOLOGICAL EVALUATION:
CT ARTERIAL PORTOGRAPHY:
1022 VASCULAR INVASION............
1023 BILOBAR DISEASE..............
1024 LYMPH NODES..................
1025 SIZE OF DOMINANT TUMOR (mm)..
1026 NUMBER OF TUMORS.............
SPIRAL CT:
1029 VASCULAR INVASION............
1030 BILOBAR DISEASE..............
1031 LYMPH NODES..................
1032 SIZE OF DOMINANT TUMOR (mm)..
1033 NUMBER OF TUMORS.............
INCREMENTAL CT:
1036 VASCULAR INVASION............
1037 BILOBAR DISEASE..............
1038 LYMPH NODES..................
1039 SIZE OF DOMINANT TUMOR (mm)..
1040 NUMBER OF TUMORS.............
1043 VASCULAR INVASION............
1044 BILOBAR DISEASE..............
1045 LYMPH NODES..................
1046 SIZE OF DOMINANT TUMOR (mm)..
1047 NUMBER OF TUMORS.............
1050 VASCULAR INVASION............
1051 BILOBAR DISEASE..............
1052 LYMPH NODES..................
1053 SIZE OF DOMINANT TUMOR (mm)..
1054 NUMBER OF TUMORS.............
1055 18. DEFINITIVE DIAGNOSIS..........
19. DATE OF INITIAL DIAGNOSIS.....:
22. DIAGNOSTIC CONFIRMATON........:
VASCULAR INVASION............: NA
BILOBAR DISEASE..............: NA
LYMPH NODES..................: NA
SIZE OF DOMINANT TUMOR (mm)..: Not performed
NUMBER OF TUMORS.............: Not performed
VASCULAR INVASION............: Unknown
BILOBAR DISEASE..............: Unknown
LYMPH NODES..................: Unknown
23. SIZE OF TUMOR
24. REGIONAL NODES EXAMINED
25. REGIONAL NODES POSITIVE
26. AJCC CLINICAL STAGE (cTNM)
27. AJCC PATHOLOGIC STAGE (pTNM)
28. STAGED BY
STAGE OF DISEASE AT DIAGNOSIS
29 23. SIZE OF TUMOR ................
33 24. REGIONAL NODES EXAMINED.......
32 25. REGIONAL NODES POSITIVE.......
26. AJCC CLINICAL STAGE (cTNM):
37.1 AJCC CLINICAL T..............
37.2 AJCC CLINICAL N..............
37.3 AJCC CLINICAL M..............
27. AJCC PATHOLOGIC STAGE (pTNM):
85 AJCC PATHOLOGIC T............
86 AJCC PATHOLOGIC N............
87 AJCC PATHOLOGIC M............
28. STAGED BY:
19 CLINICALLY STAGED BY.........
89 PATHOLOGICALLY STAGED BY.....
29. DATE OF FIRST COURSE OF TREATMENT
30. DATE OF INPATIENT ADMISSION
31. DATE OF INPATIENT DISCHARGE
32. DATE OF NON CANCER-DIRECTED SURGERY
33. NON CANCER-DIRECTED SURGERY
34. DATE OF CANCER-DIRECTED SURGERY
35. SURGICAL APPROACH
36. SURGERY OF PRIMARY SITE
37. RADIO-FREQUENCY DESTRUCTION OF TUMOR
39. SURGICAL MARGINS
40. DISTANCE OF TUMOR TO CLOSEST MARGIN
41. SURGERY OF REGIONAL SITE(S), DISTANT SITE(S), OR DISTANT LYMPH NODE(S)
42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR
43. RECONSTRUCTION/RESTORATION-FIRST COURSE
44. DATE RADIATION STARTED
45. RADIATION THERAPY
46. DATE CHEMOTHERAPY STARTED
48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED
49. ROUTE CHEMOTHERAPY ADMINISTERED
50. CHEMOTHERAPY/SURGERY SEQUENCE
OTHER THERAPY
51. DATE OTHER TREATMENT STARTED
52. OTHER TREATMENT
53. ARTERIAL EMBOLIZATION
54. DEATH WITHIN30 DAYS OF START OF INTIIAL COURSE OF THERAPY
FIRST COURSE OF TREATMENT
29. DATE OF FIRST COURSE OF
1 30. DATE OF INPATIENT ADMISSION...
1.1 31. DATE OF INPATIENT DISCHARGE...
32. DATE OF NON CANCER-DIRECTED
33. NON CANCER-DIRECTED SURGERY...:
34. DATE OF CANCER-DIRECTED
35. SURGICAL APPROACH.............:
36. SURGERY OF PRIMARY SITE.......:
37. RADIO-FREQUENCY DESTRUCTION OF
1056 37. RADIO-FREQUENCY DESTRUCTION OF TUMOR........................
38. ABLATION & RESECTION..........: Ablation & resection not administered
39. SURGICAL MARGINS..............:
40. DISTANCE OF TUMOR TO CLOSEST
1058 40. DISTANCE OF TUMOR TO CLOSEST MARGIN.......................
41. SURGERY OF OTHER REGIONAL
SITE(S), DISTANT SITE(S),
OR DISTANT LYMPH NODE(S).....:
42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR:
FIRST COURSE.................:
44. DATE RADIATION STARTED........:
45. RADIATION THERAPY.............:
46. DATE CHEMOTHERAPY STARTED.....:
48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
CISPLATIN....................: Unknown if recommended or administered
FUDR.........................: Unknown if recommended or administered
5-FU.........................: Unknown if recommended or administered
FU & LEUCOVORIN..............: Unknown if recommended or administered
IRINOTECAN (CPT-11)..........: Unknown if recommended or administered
MITOMYCIN C..................: Unknown if recommended or administered
OXALIPLATIN..................: Unknown if recommended or administered
GEMCITABINE..................: Unknown if recommended or administered
49. ROUTE CHEMOTHERAPY ADMIN......: NA
1069 49. ROUTE CHEMOTHERAPY ADMIN
50. CHEMOTHERAPY/SURGERY SEQUENCE.: No chemotherapy and/or no surgery
50. CHEMOTHERAPY/SURGERY SEQUENCE.: Chemotherapy before surgery
1070 50. CHEMOTHERAPY/SURGERY SEQUENCE.
OTHER THERAPY
51. DATE OTHER TREATMENT STARTED..:
52. OTHER TREATMENT...............:
1071 53. ARTERIAL EMBOLIZATION.........
1072 54. DEATH WITHIN 30 DAYS OF START OF INITIAL COURSE OF THERAPY.
55. DATE OF FIRST RECURRENCE
56. TYPE OF FIRST RECURRENCE
55. TYPE OF FIRST RECURRENCE
56. DATE OF FIRST RECURRENCE
70 55. DATE OF FIRST RECURRENCE
71 56. TYPE OF FIRST RECURRENCE
57. DATE OF LAST CONTACT OR DEATH
58. VITAL STATUS
59. CANCER STATUS
57. DATE OF LAST CONTACT OR DEATH..:
15 58. VITAL STATUS...................
59. CANCER STATUS..................:
1. FACILITY ID NUMBER (FIN)....:
2. ACCESSION NUMBER............:
3. SEQUENCE NUMBER.............:
4. POSTAL CODE AT DIAGNOIS.....:
5. PLACE OF BIRTH..............:
6. DATE OF BIRTH...............:
8. SPANISH ORIGIN..............:
10. PRIMARY PAYER AT DIAGNOSIS..:
TUMOR IDENTIFICATION
11. CLASS OF CASE...............:
ORAL CONTRACEPTIVES........:
ESTROGEN REPLACEMENT.......:
14. ALCOHOL CONSUMPTION.........:
15. TUMOR MARKERS:
16. TESTS RELATED TO LIVER FUNCTION:
CT ARTERIAL PORTOGRAPHY:
VASCULAR INVASTION.........:
BILOBAR DISEASE............:
LYMPH NODES................:
SIZE OF DOMINANT TUMOR (MM):
NUMBER OF TUMORS...........:
SPIRAL CT:
INCREMENTAL CT:
18. DEFINITIVE DIAGNOSIS........:
19. DATE OF INITIAL DIAGNOSIS...:
22. DIAGNOSTIC CONFIRMATION.....:
Print Hepatocellular Cancer PCE
STAGE OF DISEASE AT DIAGNOSIS
23. SIZE OF TUMOR...............:
24. REGIONAL NODES EXAMINED.....:
25. REGIONAL NODES POSITIVE.....:
26. AJCC CLINICAL STAGE (cTNM):
AJCC CLINICAL T............:
AJCC CLINICAL N............:
AJCC CLINICAL M............:
AJCC CLINICAL STAGE GROUP..:
27. AJCC PATHOLOGIC STAGE (pTNM):
AJCC PATHOLOGIC T..........:
AJCC PATHOLOGIC N..........:
AJCC PATHOLOGIC M..........:
AJCC PATHOLOGIC STAGE GROUP:
28. STAGED BY:
CLINICALLY STAGED BY.......:
PATHOLOGICALLY STAGED BY...:
FIRST COURSE OF TREATMENT
29. DATE OF FIRST COURSE OF
30. DATE OF INPATIENT ADMISSION.:
31. DATE OF INPATIENT DISCHARGE.:
32. DATE OF NON CANCER-DIRECTED
33. NON CANCER-DIRECTED SURGERY.:
34. DATE OF CANCER-DIRECTED
35. SURGICAL APPROACH...........:
36. SURGERY OF PRIMARY SITE.....:
37. RADIO-FREQUENCY DESTRUCTION
OF TUMOR...................:
39. SURGICAL MARGINS............:
40. DISTANCE OF TUMOR TO CLOSEST
41. SURGERY OF OTHER REGIONAL
OR DISTANT LYMPH NODE(S)...:
FIRST COURSE...............:
44. DATE RADIATION STARTED......:
45. RADIATION THERAPY...........:
46. DATE CHEMOTHERAPY STARTED...:
49. ROUTE CHEMOTHERAPY ADMIN....:
50. CHEMOTHERAPY/SURGERY SEQ....:
51. DATE OTHER TREATMENT STARTED:
52. OTHER TREATMENT.............:
53. ARTERIAL EMBOLIZATION.......:
54. DEATH WITHIN 30 DAYS OF
START OF INITIAL COURSE OF
55. DATE OF FIRST RECURRENCE....:
56. TYPE OF FIRST RECURRENCE....:
57. DATE OF LAST CONTACT/DEATH..:
58. VITAL STATUS................:
59. CANCER STATUS...............:
The Class of Case code is not 0, 1, 2 or 5.
The Behavior Code is not 0, 1 or 3.
2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors
2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors
10. PRIOR EXPOSURE TO RADIATION
11. PRIMARY PAYER AT DIAGNOSIS
12. PRIOR MEDICAL CONDITIONS
14. GENETIC PREDISPOSITION
15. USUAL OCCUPATION
16. USUAL INDUSTRY
5. DATE OF BIRTH.................:
9 7. SPANISH ORIGIN................
403 10. PRIOR EXPOSURE TO RADIATION...
18 11. PRIMARY PAYER AT DIAGNOSIS....
12. PRIOR MEDICAL CONDITIONS:
1202 MULTIPLE SCLEROSIS (MS)......
354 MYOCARDIAL INFARCTION (MI)...
1204 CEREBROVASCULAR DISEASE......
1208 MALIGNANT MELANOMA...........
1209 OTHER SKIN CANCER............
1211 COLON OR OTHER GI CANCERS....
14. GENETIC PREDISPOSITION:
1214 VON HIPPEL-LINDAU DISEASE....
1215 TUBEROUS SCLEROSIS...........
1216 TURCOT SYNDROME..............
1217 LI-FRAUMENI SYNDROME.........
1218 KOWDEN DISEASE...............
1219 NEVOID BASAL CELL CARCINOMA..
15. USUAL OCCUPATION..............:
16. USUAL INDUSTRY................:
17. CLASS OF CASE
19. NEUROLOGICAL FINDINGS
20. PRE-THERAPY DIAGNOSTIC STUDIES
21. TUMOR LOCATION/INVOLVEMENT
#################### #################### ####################
#################### #################### ####################
#################### #################### ####################
#################### #################### ####################
#################### #################### ####################